Publications by authors named "Jeng Pyng Shaw"

Claim this Profile
D
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
R Murray McKinnell, Scott R Armstrong, David T Beattie, Paul R Fatheree, Daniel D Long, Jeng-Pyng Shaw

Bioorg Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
Daniel D Long, Bryan Frieman, Sharath S Hegde, Craig M Hill, Lan Jiang, Jeng-Pyng Shaw

Bioorg Med Chem Lett· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
Daniel D Long, Scott R Armstrong, David T Beattie, Seok-Ki Choi, Paul R Fatheree, Jeng-Pyng Shaw

Bioorg Med Chem Lett· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
Daniel D Long, Scott R Armstrong, David T Beattie, Seok-Ki Choi, Paul R Fatheree, Jeng-Pyng Shaw

Bioorg Med Chem Lett· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of telavancin in healthy subjects and patients with infections.
Emil Samara, Jeng-Pyng Shaw, Steven L Barriere, Shekman L Wong, Philip Worboys

Antimicrob Agents Chemother· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.
Sharath S Hegde, Olanrewaju O Okusanya, Robert Skinner, Jeng-Pyng Shaw, Glenmar Obedencio

Antimicrob Agents Chemother· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic.
Jeng-Pyng Shaw, Sarah Jaw-Tsai

Xenobiotica· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a putative regulator of early T cell activation genes. Science. 1988. 241: 202-205.
Jeng-Pyng Shaw, Paul J Utz, David B Durand, J Jay Toole, Elizabeth Ann Emmel

J Immunol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers.
Jeng-Pyng Shaw, Jonathan Cheong, Michael R Goldberg, Michael M Kitt

Antimicrob Agents Chemother· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women.
Michael R Goldberg, Shekman L Wong, Jeng-Pyng Shaw, Michael M Kitt, Steven L Barriere

Pharmacotherapy· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.
Michael R Goldberg, Shekman L Wong, Jeng-Pyng Shaw, Michael M Kitt, Steven L Barriere

Pharmacotherapy· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
Mark H Gotfried, Jeng-Pyng Shaw, Bret M Benton, Kevin M Krause, Michael R Goldberg

Antimicrob Agents Chemother· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue penetration of telavancin after intravenous administration in healthy subjects.
Heather K Sun, Kenneth Duchin, Charles H Nightingale, Jeng-Pyng Shaw, Julie Seroogy

Antimicrob Agents Chemother· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
Sharath S Hegde, Noe Reyes, Tania Wiens, Nicole Vanasse, Robert Skinner, Jeng-Pyng Shaw

Antimicrob Agents Chemother· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing the efficiency of pharmacokinetic sample procurement, preparation and analysis by liquid chromatography/tandem mass spectrometry.
Josephine S Villa, Robert T Cass, Dane E Karr, Stacy M Adams, Jeng-Pyng Shaw

Rapid Commun Mass Spectrom· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).
Michael R Leadbetter, Stacy M Adams, Bettina Bazzini, Paul R Fatheree, Dane E Karr, Jeng-Pyng Shaw

J Antibiot (Tokyo)· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vancomycin disulfide derivatives as antibacterial agents.
YongQi Mu, Matthew Nodwell, John L Pace, Jeng Pyng Shaw, J Kevin Judice

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis